MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cvr/cvae191

Медицинская библиотека · Cardiovascular research · 2025

Optical coherence tomography assessment of the impact of colchicine on non-culprit coronary plaque composition after myocardial infarction.

Psaltis Peter J, Nguyen Mau T, Singh Kuljit, Sinhal Ajay, Wong Dennis T L, Alcock Richard, Rajendran Sharmalar, Dautov Rustem, Barlis Peter, Patel Sanjay, Salagaras Thalia, Marathe Jessica A, Bursill Christina A, Montarello Nicholas J, Nidorf Stefan M, Thompson Peter L, Butters Julie, Cuthbert Alana R, Yelland Lisa N, Ottaway Juanita L, Kataoka Yu, Di Giovanni Giuseppe, Nicholls Stephen J

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

AIMS: Low-dose colchicine reduces the risk of cardiovascular events after myocardial infarction (MI). The purpose of this study was to assess the effect of colchicine post-MI on coronary plaque morphology in non-culprit segments by optical coherence tomography (OCT).

METHODS AND

RESULTS

COCOMO-ACS was a double-blind, placebo-controlled trial that randomized 64 patients (median age 61.5 years; 9.4% female) with acute non-ST-segment elevation MI to colchicine 0.5 mg daily or placebo for a median of 17.8 months in addition to guideline-recommended therapy. Participants underwent serial OCT imaging within a matched segment of non-culprit coronary artery that contained at least one lipid-rich plaque causing ≥20% stenosis. The primary outcome was the change in minimum fibrous cap thickness (FCT) in non-culprit segments from baseline to final visit. Of those randomized, 57 (29 placebo, 28 colchicine) had evaluable imaging at baseline and follow-up. Overall, colchicine had no effect on relative (placebo +48.0 ± 35.1% vs. colchicine +62.4 ± 38.1%, P = 0.18) or absolute changes in minimum FCT (+29.2 ± 20.9 µm vs. + 37.2 ± 21.3 µm, P = 0.18), or change in maximum lipid arc (-38.8 ± 32.2° vs. -54.8 ± 46.9°, P = 0.18) throughout the imaged non-culprit segment. However, in patients assigned colchicine, cap rupture was less frequent (placebo 27.6% vs. colchicine 3.6%, P = 0.03). In post hoc analysis of 43 participants who had been followed for at least 16 months, minimum FCT increased to a greater extent in the colchicine group (placebo +38.7 ± 25.4% vs. colchicine +64.7 ± 34.1%, P = 0.005).

CONCLUSION

In this study, OCT failed to detect an effect of colchicine on the minimum FCT or maximum lipid arc of plaques in non-culprit segments post-MI. The post hoc observation that minimum FCT increased to a greater extent with colchicine after more prolonged treatment suggests that longer-term studies may be required to detect the effect of anti-inflammatory therapies on plaque morphology by OCT.

CLINICAL TRIAL NUMBER: Australian New Zealand Clinical Trials Registry Identifier, ACTRN12618000809235, registered on the 11 May 2018.

Для цитирования: Psaltis Peter J, Nguyen Mau T, Singh Kuljit, Sinhal Ajay, Wong Dennis T L, Alcock Richard, Rajendran Sharmalar, Dautov Rustem, Barlis Peter, Patel Sanjay, Salagaras Thalia, Marathe Jessica A, Bursill Christina A, Montarello Nicholas J, Nidorf Stefan M, Thompson Peter L, Butters Julie, Cuthbert Alana R, Yelland Lisa N, Ottaway Juanita L, Kataoka Yu, Di Giovanni Giuseppe, Nicholls Stephen J. Optical coherence tomography assessment of the impact of colchicine on non-culprit coronary plaque composition after myocardial infarction.. Cardiovascular research. 2025. DOI: 10.1093/cvr/cvae191.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.